Recent News

• 06.10.2025 - Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
• 06.10.2025 - Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
• 05.15.2025 - Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update
• 05.15.2025 - Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update
• 05.12.2025 - Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
• 05.12.2025 - Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
• 04.15.2025 - Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress
• 04.15.2025 - Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress
• 03.31.2025 - Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update
• 03.31.2025 - Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

Recent Filings

• 05.15.2025 - 8-K Current report
• 05.15.2025 - EX-99.1 EX-99.1
• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.12.2025 - EX-99.1 EX-99.1
• 05.12.2025 - 8-K Current report
• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.31.2025 - EX-99.1 EX-99.1
• 03.31.2025 - 8-K Current report
• 03.05.2025 - 8-K Current report
• 03.05.2025 - 4 Statement of changes in beneficial ownership of securities